Cancer Gene Therapy Market

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), by End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories), by Geography (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, Australia, India, Brazil, Mexico, South Africa, Saudi Arabia) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

Delivery : 24-72 Working Hours
Report Code: LS11358
Available Format:
Category : Healthcare

Cancer Gene Therapy Market Overview

The global cancer gene therapy market is expected to attain lucrative growth in the forecast period mainly due to rise in funding for R&D activities for cancer gene therapy, increasing prevalence of cancer, and rapid technological advancements being witnessed in the market. Gene therapy is used for the treatment of cancer, where a functional gene is inserted into the cells of a patient to correct a genetic abnormality and provide new function to the cells.

The cancer gene therapy market is segmented on the basis of various therapies used for treatment and end user. Gene induced immunotherapy, oncolytic virotherapy, and gene transfer are the different therapies used for the treatment of cancer. Gene transfer therapies holds the largest share in the global market and the category is also expected to witness fastest growth in demand during the forecast period. The key end users in the cancer gene therapy market include hospitals, oncology institutes, biotechnological companies and clinical research laboratories.

Cancer Gene Therapy Market Dynamics

Growth Drivers

Increasing funding for R&D activities for cancer gene therapy, rising prevalence of cancer, rapid technological advancements, growing geriatric population, ethical acceptance of gene therapy for treatment of diseases, growing popularity of DNA vaccines and favorable government regulations are some of the key factors characterizing the growth in the cancer gene therapy market, globally. According to the American Cancer Society (ACS), around 1,688,780 new cancer cases are expected to be diagnosed, in the U.S., in 2017. Almost, 600,920 Americans are expected to die of cancer in 2017, indicating that around 1,650 cancer patients are dying per day, due to the disease. In 2013, the World Health Organization (WHO) launched the Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020, that aimed at reducing the rate of premature mortality from cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases by 25%, by 2025.

Due to the increasing prevalence of cancer worldwide there are several organizations that are investing in cancer research. For instance, in October 2017, the ACS, approved funding for 78 research and training grants totaling $39.8 million in the second of two grant cycles. The grants will fund investigators in 57 institutions across the U.S.; among these 63 are new grants while 15 are renewals of previous grants.

As of August 2017, around 159 grants worth $28.6 million have been provided for the research of breast cancer by the ACS. The American Association for Cancer Research (AARC), has granted $331.0 million to approximately 606 recipients in 13 countries around the world for cancer research from 1993-2016, indicating significant amount of development in the field of cancer research.


Innovation therapies with better success rates, ethical acceptance of gene therapy for cancer treatment and untapped markets in developing economies are expected to offer various growth opportunities for the players in the cancer gene therapy market. For instance, in August 2017, the United States Food and Drug Administration (USFDA) approved a breakthrough treatment for children suffering with acute lymphoblastic leukemia (ALL) using CAR T therapy, also known as Kymriah, developed at the University of Pennsylvania’s Abramson Cancer Center.

This is the first gene therapy treatment approved for cancer by the USFDA. Further, Novartis International AG, has licensed this technology and making it possible to manufacture the CAR T cells on a larger scale. The company plans to make Kymriah available at around 30 hospitals nationwide by the end of 2018.

Cancer Gene Therapy Market Insights by Geography

North America is expected to lead the global cancer gene therapy market throughout the forecast period (2018–2023) followed by the Europe. This is mainly due to strong healthcare infrastructure and high expenditure in R&D in North America. The healthcare industry in the region is undergoing major transformation following the implementation of various healthcare reforms.

Asia-Pacific (APAC) is expected to grow at the fastest CAGR during the forecast period. The region has been observing increased government initiatives, growing economies and improved healthcare infrastructure. Increasing focus on the development of healthcare infrastructure in the developing countries of the region is expected to provide ample growth opportunities for the market players. These opportunities are largely attributed to increasing disposable income of the population residing in the emerging markets, which is further increasing the affordability for advanced treatment options among the patients suffering from diseases such as cancer, thereby boosting the growth of cancer gene therapy market in the region.

Additionally, emerging countries, such as India, and Korea, are characterized by a huge patient pool, which can be attributed to the increasing burden of non-communicable diseases and rising geriatric population in these countries. According to the WHO, chronic diseases are estimated to increase by 57% by 2020, globally. Thus, APAC offers significant growth opportunities for the market players.

Cancer Gene Therapy Competitive Landscape

The players in the global market have been receiving approvals for the cancer gene therapy treatments to provide better treatment to cancer patients, thus increasing their market share. For instance, in December 2017, Celgene Corporation and bluebird bio, Inc. announced the updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients suffering with late-stage relapsed/refractory multiple myeloma.

In November 2017, ZIOPHARM Oncology, Inc. announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the company's controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer, at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).

In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and initiated a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, the U.K. Some of the other key players operating in the cancer gene therapy industry include Genelux Corporation, Cell Genesys, Advantagene Inc., GenVec, Inc., BioCanCell Ltd.,  Adaptimmune Therapeutics plc, Bluebird bio, Inc., and Achieve Life Sciences, Inc.

Cancer Gene Therapy Market Segmentation

By Therapy

  • Gene induced immunotherapy
    • Delivery of cytokines gene
    • Delivery of tumor antigen gene
  • Oncolytic Virotherapy
    • Adenovirus
    • Lentivirus
    • Retro virus
    • Adeno associated virus
    • Herpes simplex virus
    • Alpha virus
    • Vaccinia virus
    • Simian virus
    • Others
  • Gene Transfer
    • Naked/plasmid vectors
    • Electroporation
    • Sonoporation
    • Magnetofection
    • Gene gun

By End-User

  • Hospitals
  • Oncology institutes
  • Biotechnological companies
  • Clinical research laboratories

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific (APAC)
    • Japan
    • China
    • Australia
    • India
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry